| |
 |
Editorial [Hot Topic: Drugs Targeting Atherosclerosis: Current and Emerging Approaches (Executive Editors: Vangelis G. Manolopoulos and Anna Tavridou)]
|
| |
|
pp.3091-3093 (3) Authors: Vangelis G. Manolopoulos, Anna Tavridou
|
| |
|
|
| |
|
Anti-Atherosclerotic Molecules Targeting Oxidative Stress and Inflammation
|
| |
|
pp.3094-3107 (14) Authors: A. Adameova, Y. J. Xu, T. A. Duhamel, P. S. Tappia, L. Shan, N. S. Dhalla
|
| |
|
|
| |
|
Rho Kinase: An Important Mediator of Atherosclerosis and Vascular Disease
|
| |
|
pp.3108-3115 (8) Authors: Qian Zhou, James K. Liao
|
| |
|
|
| |
|
Inhibitors of the 5-Lipoxygenase Pathway in Atherosclerosis
|
| |
|
pp.3116-3132 (17) Author: Magnus Back
|
| |
|
|
| |
|
Prevention of Atherosclerosis by Interference with the Vascular Nitric Oxide System
|
| |
|
pp.3133-3145 (13) Authors: Huige Li, Ulrich Forstermann
|
| |
|
|
| |
|
Recent Advances on the Antiatherogenic Effects of HDL-Derived Proteins and Mimetic Peptides
|
| |
|
pp.3146-3166 (21) Authors: Maria P. Petraki, Polyxeni T. Mantani, Alexandros D. Tselepis
|
| |
|
|
| |
|
EP2300 Compounds: Focusing on the Antiatherosclerotic Properties of Squalene Synthase Inhibitors
|
| |
|
pp.3167-3178 (12) Authors: A. Tavridou, V. G. Manolopoulos
|
| |
|
|
| |
|
Oral Antidiabetic Agents: Anti-Atherosclerotic Properties Beyond Glucose Lowering?
|
| |
|
pp.3179-3192 (14) Authors: N. Papanas, E. Maltezos
|
| |
|
|
| |
|
Genomics and the Prospects of Existing and Emerging Therapeutics for Cardiovascular Diseases
|
| |
|
pp.3193-3206 (14) Authors: M. Zaiou, H. Benachour, J. B. Marteau, S. Visvikis-Siest, G. Siest
|
| |
|
|
